Clinical Trial Update: Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cryoablation in combination with pembrolizumab or avelumab for metastatic urothelial carcinoma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• BAVENCIO (AVELUMAB)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: COMPLETED